Appeal No. 1997-2512
Application No. 08/118,905
“The present invention overcomes the problems described above and
provides a method (and a corresponding vaccine) for the immunization of
cats against T. gondii challenge which eliminates the phenomenon of oocyst
shedding in the vaccinated cats.
Broadly speaking, the method of the invention involves administering
to cats (preferably orally) an effective amount of a vaccine comprising a
specific mutant of T. gondii which has been found to immunize 84% of cats
without the need of chemoprophylaxis.”
See column 2, lines 38-47. The T. gondii vaccine is the subject of dependent claim 15
and falls within the scope of “biological or pharmaceutical material” as recited in appealed
claim 12. See page 4, line 8 to page 10, line 21.
Frenkel describes the administration of the vaccine to cats as follows:
“Clones of Ara-A resistant Toxoplasma were grown in human
fibroblast tissue cultures for short periods of time, but were normally
maintained as chronic infections in mice. These were injected either
subcutaneously (sc) or intraperitoneally (ip) and to prevent illness and permit
development of bradyzoites in tissue cysts, the mice were treated from days
3 to 14 with sulfamerazine-sodium (Sigma Chemical Co., St. Louis, MO) 15
mg/ 100 ml of water, given ad libitum to drink. After at least one month, a
mouse infected with a particular strain was killed, bled to be checked for the
development of antibody, and a brain smear examined by light microscopy
for the presence of cysts of Toxoplasma. The carcass of a mouse infected
with a given candidate strain was then fed to one or several seronegative,
weaned kittens and the feces were examined for the presence of oocysts
over the next 30 days.”
11
Page: Previous 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 Next
Last modified: November 3, 2007